Heren Health(300550)2022-10-27 16:00Financial Performance - The company's revenue for Q3 2022 was ¥94,741,694.44, representing a decrease of 17.00% compared to the same period last year[5] - Net profit attributable to shareholders was ¥5,541,534.18, down 65.47% year-on-year[5] - Basic earnings per share decreased by 66.67% to ¥0.02 compared to ¥0.06 in the same quarter last year[6] - Total operating revenue for Q3 2022 was CNY 302,921,946.11, a decrease of 0.33% from CNY 305,919,027.71 in Q3 2021[23] - Net profit for Q3 2022 was CNY 23,941,170.63, down 31.25% from CNY 34,796,421.82 in the same period last year[24] - Total operating costs decreased to CNY 261,258,375.67 from CNY 272,107,103.17, reflecting a reduction of 4.67%[23] - The total comprehensive income for the third quarter was CNY 23,941,170.63, a decrease from CNY 34,796,421.82 in the previous year[25] - Basic and diluted earnings per share were both CNY 0.09, down from CNY 0.13 in the same period last year[25] Cash Flow and Liquidity - The operating cash flow for the period was negative at -¥147,466,884.77, a decline of 119.74% compared to the previous year[5] - Cash inflow from operating activities was CNY 226,793,262.37, compared to CNY 296,530,801.13 in the previous year, reflecting a decline of approximately 23.5%[26] - The net cash flow from operating activities was negative at CNY -147,466,884.77, worsening from CNY -67,109,043.00 in the previous year[27] - Cash inflow from investment activities totaled CNY 458,778,694.84, significantly lower than CNY 1,124,836,930.68 in the previous year[27] - The net cash flow from investment activities was CNY 189,463,645.32, an increase from CNY 34,002,123.13 in the previous year[27] - Cash inflow from financing activities was CNY 120,000,000.00, up from CNY 110,000,000.00 in the previous year[27] - The net cash flow from financing activities improved to CNY 46,739,530.23, compared to a negative CNY -96,387,211.95 in the previous year[27] - The ending cash and cash equivalents balance was CNY 539,080,425.47, an increase from CNY 301,952,905.66 in the previous year[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,590,749,783.87, an increase of 4.64% from the end of the previous year[6] - Total liabilities increased to CNY 412,140,101.88 from CNY 359,098,514.51, representing a rise of 14.77%[21] - Current liabilities totaled CNY 409,062,918.63, up from CNY 356,555,059.88, indicating an increase of 14.66%[21] - The company's financial assets decreased by 99.27% to CNY 1,360,000 due to a reduction in investment financial products[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,693[12] - The largest shareholder, Hangzhou Panyuan Investment Co., Ltd., holds 44.32% of the shares, with 65,379,417 shares pledged[12] - The company completed a share transfer agreement where Hangzhou Panyuan Investment Co., Ltd. transferred 78,795,276 shares to Tongce Medical for a total price of RMB 769,041,893, representing a significant transaction impacting ownership structure[17] - Following the share transfer, Tongce Medical will hold approximately 29.99% of the company’s total shares, while Hangzhou Panyuan will hold 14.33%[17] - The company’s total share capital decreased due to the repurchase and cancellation of restricted shares in September 2022, affecting the percentage ownership of the transferred shares[17] - The top ten unrestricted shareholders include Hangzhou Panyuan Investment Co., Ltd. with 116,454,980 shares, representing a substantial portion of the company’s equity[13] Operational Insights - The company did not report any new product developments or market expansion strategies during the quarter[5] - The company’s management has indicated plans for future market expansion and potential new product development, although specific details were not disclosed in the report[16] - Research and development expenses increased to CNY 40,258,379.00, up 14.06% from CNY 35,048,778.93[24] - Development expenditures surged by 173.35% to CNY 34,335,088.31, mainly due to the capitalization of completed R&D projects[9] Other Financial Metrics - Non-recurring gains and losses for the period totaled -¥819,160.82, with a year-to-date total of ¥2,901,295.54[7] - The company reported a decrease in net profit after deducting non-recurring items by 55.52% to ¥6,360,695.00[5] - The company's net profit margin decreased to 0.48% from 1.42% in the previous year[6] - Cash received from sales decreased by 30.92% to CNY 185,279,514.21, impacted by reduced sales collections[10] - The company reported a 950.67% increase in credit impairment losses, amounting to CNY -19,343,718.86, due to decreased sales collections[9] - The company's financial report indicates a strong liquidity position with a notable increase in current assets compared to the previous year[19] - The report for the third quarter was not audited[28]